H.R. 5810 — what changed
Medicaid Health Homes for Opioid-Use-Disorder Medicaid Enrollees Encouraged Act
From Introduced in House to Reported in House. 1 added between Introduced in House and Reported in House.
Sec. 3 Requirement for State Medicaid plans to provide coverage for medication-assisted treatment
addedadded “(29) subject to paragraph (2) of subsection (ee), for the period beginning October 1, 2020, and ending September 30, 2025, medication-assisted treatment (as defined in paragraph (1) of such subsection); and”
added “(ee) Medication-assisted treatment
added “(1) Definition—For purposes of subsection (a)(29), the term “medication-assisted treatment”—
added “(A) means all drugs approved under section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355), including methadone, and all biological products licensed under section 351 of the Public Health Service Act (42 U.S.C. 262) to treat opioid use disorders; and
added “(B) includes, with respect to the provision of such drugs and biological products, counseling services and behavioral therapy.
added “(2) Exception—The provisions of paragraph (29) of subsection (a) shall not apply with respect to a State for the period specified in such paragraph, if before the beginning of such period the State certifies to the satisfaction of the Secretary that implementing such provisions statewide for all individuals eligible to enroll in the State plan (or waiver of the State plan) would not be feasible by reason of a shortage of qualified providers of medication-assisted treatment, or facilities providing such treatment, that will contract with the State or a managed care entity with which the State has a contract under section 1903(m) or under section 1905(t)(3).”